News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
11,192 Results
Type
Article (1321)
Company Profile (4)
Press Release (9867)
Section
Business (3264)
Career Advice (41)
Deals (557)
Drug Delivery (47)
Drug Development (1637)
Employer Resources (4)
FDA (441)
Job Trends (258)
News (5811)
Policy (621)
Tag
Academia (27)
Alliances (875)
Alzheimer's disease (29)
Approvals (429)
Artificial intelligence (11)
Bankruptcy (6)
Best Places to Work (163)
Cancer (29)
Cardiovascular disease (22)
Career advice (28)
Cell therapy (10)
Clinical research (1238)
Collaboration (25)
COVID-19 (36)
C-suite (4)
Data (37)
Diabetes (67)
Diagnostics (128)
Drug pricing (39)
Drug shortages (16)
Earnings (947)
Editorial (11)
Events (1201)
Executive appointments (13)
FDA (465)
Funding (34)
Gene therapy (9)
GLP-1 (372)
Government (138)
Healthcare (390)
Infectious disease (36)
IPO (253)
IRA (12)
Job creations (106)
Job search strategy (27)
Layoffs (22)
Legal (99)
Lung cancer (6)
Manufacturing (39)
MASH (11)
Medical device (408)
Medtech (408)
Mergers & acquisitions (318)
Metabolic disorders (236)
Neuroscience (42)
NextGen Class of 2024 (126)
Non-profit (43)
Northern California (40)
Now hiring (13)
Obesity (171)
Opinion (14)
Patents (6)
People (1098)
Phase I (360)
Phase II (536)
Phase III (455)
Pipeline (20)
Podcasts (24)
Policy (21)
Postmarket research (53)
Preclinical (133)
Psychedelics (5)
Rare diseases (13)
Real estate (101)
Regulatory (439)
Research institute (37)
Resumes & cover letters (10)
Series A (12)
Series B (8)
Sickle cell disease (6)
Southern California (25)
Startups (114)
Supply chain (15)
The Weekly (23)
United States (304)
Vaccines (9)
Weight loss (179)
Date
Last 7 days (34)
Last 30 days (92)
Last 365 days (1068)
2024 (1063)
2023 (763)
2022 (1039)
2021 (978)
2020 (916)
2019 (778)
2018 (594)
2017 (730)
2016 (536)
2015 (551)
2014 (437)
2013 (361)
2012 (395)
2011 (404)
2010 (359)
Location
Africa (20)
Asia (604)
Australia (221)
California (80)
Canada (33)
China (13)
Connecticut (5)
Europe (3046)
Florida (12)
Indiana (12)
Maryland (16)
Massachusetts (63)
Michigan (14)
Minnesota (5)
New Jersey (31)
New York (7)
North Carolina (7)
Northern California (40)
Pennsylvania (18)
South America (18)
Southern California (25)
Texas (9)
Washington State (7)
11,192 Results for "novo nordisk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
GLP-1
Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.
November 4, 2024
·
1 min read
·
Annalee Armstrong
GLP-1
EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters
Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.
December 18, 2024
·
2 min read
·
Annalee Armstrong
GLP-1
Novo’s CagriSema Blunder Underscores Sky-High Investor Expectations for Weight Loss Drugs
Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.
December 20, 2024
·
3 min read
·
Annalee Armstrong
Obesity
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data
Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s prior projections for the therapy. Meanwhile, Eli Lilly’s stock rose on the news.
December 20, 2024
·
3 min read
·
Tristan Manalac
Deals
Novo Adds Novel Approach to Cardiometabolic Pipeline With Photys Collab
Photys is eligible for up to $186 million from Novo Nordisk for its PHICS small molecules that pair a kinase to a disease-causing protein for phosphorylation.
December 18, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
December 16, 2024
·
2 min read
GLP-1
Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study
Adding to growing evidence of its benefits beyond glucose control and weight loss, Novo Nordisk’s Ozempic could also potentially help diabetics quit smoking, according to new research.
July 30, 2024
·
2 min read
·
Tristan Manalac
GLP-1
Novo’s Wegovy Comparable to Madrigal’s Rezdiffra in Phase III MASH Trial: Analysts
In part 1 of the pivotal ESSENCE trial, Novo Nordisk’s weight loss drug Wegovy demonstrated “statistically significant and superior improvement” in liver fibrosis in patients with metabolic dysfunction–associated steatohepatitis.
November 1, 2024
·
3 min read
·
Heather McKenzie
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
December 19, 2024
·
1 min read
1 of 1,120
Next
